Drugs / BCG Organism
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07182838 | Sep 2025 → Aug 2026 overdue | HIV infectious disease | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG Organism | “HIV GP160 0.1 mg x 1 mL plus BCG Organism 50 MG Mix” NCT07182838 ↗ |
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07182838 ↗ |
| Modality | Vaccine | “BCG Vaccine Mix” NCT07182838 ↗ |
| Route | Other | “By the percutaneous route with the multiple puncture device” NCT07182838 ↗ |